MDS Virtual Congress 2020 » Huntington's Disease

Meeting: MDS Virtual Congress 2020

A longitudinal PET study to assess the state of microglia activation in a Phase 2 study of Laquinimod as a treatment for Huntington’s disease (LEGATO-HD)

A.A Roussakis, M. Gennaro, M.F Gordon, R. Reilmann, B. Borowsky, G. Rynkowski, J.M Savola, M.R Hayden, R. Gunn, S. Tabrizi, P. Piccini (London, United Kingdom)

Association between the number of CAG repetitions and cognitive performance in Huntington’s disease in patients of the National Institute of Neurology and Neurosurgery “MVS”

D. Gasca-Saldaña, A. Vega-Rosas, G. Palma-Cordero, O. Castellanos-Maya (CDMX, Mexico)

Biological and Clinical Manifestations of Huntington’s disease in Gene Carriers Very Far from Predicted Onset: The Young Adult Study

P. Zeun, R. Scahill, K. Osborne-Crowley, E. Johnson, S. Gregory, C. Parker, J. Lowe, A. Nair, C. O'Callaghan, C. Langley, M. Papoutsi, P. McColgan, C. Estevez-Fraga, K. Fayer, H. Wellington, F. Rodrigues, L. Byrne, A. Heselgrave, H. Hyare, C. Sampaio, H. Zetterberg, H. Zhang, E. Wild, G. Rees, T. Robbins, B. Sahakian, D. Langbehn, S. Tabrizi (London, United Kingdom)

Burden of Huntington’s disease (HD) on loss of employment status and its association with disease stage

J. Ko, X. Lu, A. Exuzides, R. Fuller, J. Luo (South San Francisco, CA, USA)

Can Handwriting Movement Abnormalities Serve as an Early Biomarker of Transition to Manifest Huntington’s disease?

J. Corey-Bloom, A. Hall, C. Snell, B. Wright, M. Caligiuri (La Jolla, CA, USA)

Cardiovascular risk factors in a pre-manifest and manifest population of Huntington’s disease

E. Gatto, N. Gonzalez Rojas, M. Cesarini, J. Etcheverry, G. Da Prat (Buenos Aires, Argentina)

Changes in fecal microbiota composition in patients with Huntington’s disease in China

G. Du, W. Dong, Q. Yang, Y. Huang (Beijing, China)

Cytokines and Brain Specific Antibodies in Experimental Cellular and Molecular Treatment of Huntington’s Diseases

D. Labunskiy, S. Kiryukhina, V. Podsevatkin (Saransk, Russian Federation)

Defining time and anatomical specificity of basal ganglia white matter loss in premanifest Huntington’s disease

P. Zeun, P. McColgan, T. Dhollander, S. Gregory, E. Johnson, M. Papoutsi, R. Scahill, G. Rees, S. Tabrizi (London, United Kingdom)

Detection of Cognitive Changes in Premanifest Huntington’s disease Using the Repeatable Battery for the Assessment of Neuropsychological Status

A. Mustafa, J. Corey-Bloom, H. Smith, J. Castleton, P. Gilbert (San Diego, CA, USA)

Deutetrabenazine for Huntington’s disease chorea—A Single Center’s Experience

D. Fischer, R. Caskey, M. Dean, V. Sung (Birmingham, AL, USA)

Development of a time-to-event endpoint for use in premanifest Huntington’s disease (HD) clinical trials

S. Rossomanno, H. Guthrie, E.J Wild, S.A Schobel, L. Boak, D. Trundell (Basel, Switzerland)

Differential burden of comorbidities for Huntington’s Disease, Parkinson’s Disease and the general population for patients and care partners in the US

A. Exuzides, J. Matos, B. Ricker, D. Bega (South San Francisco, CA, USA)

Epidemiology of Huntington’s Disease (HD) in the US Medicaid Population

A. Exuzides, S. Reddy, E. Chang, C. Paydar, G. Yohrling (South San Francisco, CA, USA)

Evaluation of Cortical Excitability in Huntington’s Disease and Parkinson’s Disease

N. Togashi, M. Hamada, Y. Shirota, T. Toda, K. Nishiyama, K. Hasegwa (Sagamihara, Japan)

Evaluation of the Safety of Deutetrabenazine at Higher Doses to Treat Chorea in Huntington’s Disease

S. Frank, C. Vaughan, D. Stamler, D. Oakes, M. Davis, N. Gross, M. Gordon, J.M Savola, M. Wieman, S. Eberly, E. Kayson, J. Whaley, J. Goldstein, C. Testa (Boston, MA, USA)

Genetic analysis of Huntington’s Disease in a Brazilian Amazonian population

D. Brito, M. Della Coletta, G. Ferreira, L. Amorim, S. Souza, S. Peixoto, C. Rezende (Manaus, Brazil)

HD Constellation: A novel patient-centred approach to enriching clinical datasets by combining medical record chart review and Enroll-HD

K. Belendiuk, J.P Sacksteder, X. Sanii, E. Neacy, J. Levey, E. Korner, R. Houghton, G. Yohrling (South San Francisco, CA, USA)

Healthcare resource utilisation and costs among patients with versus without Huntington’s disease in the US population

A. Exuzides, T.M To, I. Abbass, A. Surinach, R. Fuller, J. Luo (South San Francisco, CA, USA)

Healthcare Utilization and Cost Burden at the End-of-Life Among Medicare Beneficiaries with Huntington’s Disease

S. Reddy, A. Exuzides, E. Chang, C. Paydar, G. Yohrling (Beverly Hills, CA, USA)

How Well Does the Composite Unified Huntington’s Disease Rating Scale (cUHDRS) Reflect Disease Progression in Huntington’s disease (HD)?

C. Snell, H. Smith, J. Castleton, A. Hall, A. Smirnova, B. Wright, P. Gilbert, J. Corey-Bloom (La Jolla, CA, USA)

Huntington’s disease in Egypt; A big challenge for a mysterious disease

S. El-Jaafary, A. Sabbah, H. Amer (Cairo, Egypt)

Huntington’s Disease in Israel – 20 years of follow up from Maccabi Healthcare Services

Y. Barer, N. Gavrielov, P. Coloma, M. Martinec, I. Korolev, I. Goldshtein (Tel Aviv, Israel)

Longitudinal dynamics of mutant huntingtin and neurofilament light in Huntington’s disease: the prospective HD-CSF study

F. Rodrigues, L. Byrne, R. Tortelli, E. Johnson, P. Wijeratne, M. Arridge, E. De Vita, D. Alexander, S. Tabrizi, S. Schobel, R. Scahill, A. Heslegrave, H. Zetterberg, E. Wild (London, United Kingdom)

Longitudinal Utility of the Montreal Cognitive Assessment and Mini Mental State Exam in Huntington’s disease (HD)

I. Beltran-Najera, J. Corey-Bloom, C. Snell, A. Smirnova, P. Gilbert (San Diego, CA, USA)

Modelling Huntington’s disease diagnosed prevalence from diagnosed incidence and survival time

V. Crowell, R. Houghton, F. Squitieri, A. Tomar, T. Fernandes (Basel, Switzerland)

Motor and non-motor symptoms in Huntington’s disease patients in the Tomsk region, Russia

M. Nikitina, V. Alifirova, K. Nurzhanova, N. Zhukova (Tomsk, Russian Federation)

Performance at the Category-Exemplars language test (CATEX) in Parkinson’s disease and Huntington’s disease Italian population

R. Biundo, T. Gandolfi, M. Garon, E. Fiorenzato, G. Arcara, C. Jaquemont, P. Bisiacchi, C. Semenza, A. Antonini (Venice-Lido, Italy)

Pridopidine for the Treatment of Early Huntington’s Disease

M. Geva, R. Reilmann, C. Olanow, M. Leinonen, Y. Cohen, P. Meyer, A. McGarry, O. Sabri, M. Hayden, K. Kieburtz (Herzliya, Israel)

Remote and frequent assessment of Huntington’s disease in clinical trials: Strategies for assessing and accounting for the practice effect

A. Wolfer, F. Lipsmeier, R. Tortelli, F.B Rodrigues, L.M Byrne, C. Simillion, T. Kilchenmann, A. Bamdadian, S.A Schobel, E.J Wild, M. Lindemann (Basel, Switzerland)

Sleep and Polysomnographic Abnormalities in Indian Patients with Huntington’s Disease

J. Annapureddy, S. D V, N. Kamble, P. Pal, S. Jain, B. Kutty, R. Yadav (Bangalore, India)

Speech is a sensitive marker in premanifest Huntington’s disease: exploring acoustic, cognitive and fine motor performance

A. Vogel, J. Chan, Y. Lie, J. Stout (Melbourne, Australia)

TAU pathology contributes to specific patterns of structural brain damage and neuropsychological heterogeneity in Huntington’s disease

S. Martinez-Horta, J. Perez-Perez, R. Perez-Gonzalez, A. Horta-Barba, F. Sampedro, E. Rivas-Asensio, T. Xucla, M. Guasch, A. Campolongo, C. Izquierdo-Barrionuevo, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)